XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2023
Sep. 30, 2022
Current Assets:    
Cash and cash equivalents $ 33,281,830 $ 41,711,690
Prepaid expenses 7,832,320 2,852,580
Total Current Assets 41,114,150 44,564,270
Property and equipment, net 2,010 4,100
Operating lease right-of-use asset, net 503,817 646,074
Other Assets:    
Deposits 38,062 38,062
In-process research and development 59,400,000 59,400,000
Goodwill 9,346,796 9,346,796
Total Other Assets 68,784,858 68,784,858
Total Assets 110,404,835 113,999,302
Current Liabilities:    
Accounts payable 3,079,667 1,165,378
Accrued expenses 892,874 1,405,394
Accrued compensation 1,605,445 1,762,251
Operating lease liability 212,871 196,989
Total Current Liabilities 5,790,857 4,530,012
Deferred tax liability 5,993,800 5,561,800
Operating lease liability – noncurrent 320,011 481,245
Total Liabilities 12,104,668 10,573,057
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock – $0.001 par value; 400,000,000 shares authorized; 158,857,798 and 146,211,130 shares issued and outstanding at June 30, 2023 and September 30, 2022, respectively 158,858 146,211
Additional paid-in capital 249,828,398 232,368,121
Accumulated deficit (152,287,469) (129,688,467)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 97,699,787 102,825,865
Non-controlling interest 600,380 600,380
Total Equity 98,300,167 103,426,245
Total Liabilities and Equity $ 110,404,835 $ 113,999,302